|Bid||0.0000 x 2200|
|Ask||0.0000 x 900|
|Day's Range||2.3787 - 2.8500|
|52 Week Range||1.5500 - 5.2400|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 7, 2017 - Aug 11, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||2.80|
Adynxx, Inc., (Nasdaq:ADYX), a clinical-stage biopharmaceutical company leading the development of transcription factor decoy technology and first-in-class therapeutics for the treatment of pain and inflammatory diseases, today announced May 29, 2019 as payment date for the special cash dividend announced by Alliqua Biomedical, Inc. (formerly Nasdaq:ALQA) on April 11, 2019. The special cash dividend entitled each share of Alliqua common stock outstanding as of the close of business on April 22, 2019 to receive $1.05 in cash, subject to the consummation of Alliqua’s previously announced merger transaction with Adynxx. The merger was consummated on May 3, 2019, immediately prior to which Alliqua effected a six-for-one reverse stock split.
Adynxx, Inc. (Nasdaq:ADYX), a clinical-stage biopharmaceutical company leading the development of transcription factor decoy technology and first-in-class therapeutics for the treatment of pain and inflammatory diseases, today announced the completion of its merger with Alliqua BioMedical, Inc.
Great progress has been made with this exciting company, including receipt of a substantial grant award from the National Institute on Drug Abuse to support the clinical development of brivoligide, the company’s lead product intended to both reduce postoperative pain and the need for opioid-based therapies. First, TOP intends to use the 20,000 patient records they developed over the past 10 years with Tikun Olam Israel, to identify the most appropriate assets to take through an FDA process with a proprietary extract, Avidekel. As a shareholder of Alliqua Biomedical, you will own shares in both of these exciting companies.
The payment of the Special Dividend is subject to the consummation of Alliqua’s previously announced merger transaction with Adynxx, Inc. (the “Adynxx Merger”), a privately held biopharmaceutical company (the “Special Dividend Condition”). In addition, the Distribution is subject to the satisfaction of all conditions to closing of the previously announced merger transaction (the “TOP Merger”) between AquaMed and TO Pharmaceuticals, LLC (“TOP”) and the substantially simultaneous consummation of the TOP Merger (the “Distribution Condition”). It is currently expected that the payment date for the Special Dividend and the distribution date for the Distribution will be as soon as practicable after satisfaction of the Special Dividend Condition and the Distribution Condition, as applicable, and in each case, no later than June 21, 2019.
Based on the positive response to that news, we continue to be encouraged about the potential these transactions have to create longer-term value for our shareholders. This transaction allowed Alliqua to strengthen our balance sheet and focus on maximizing the value of our remaining assets. In early 2018, we retained HC Wainwright to run an extensive process to determine the best way to maximize the value of our remaining assets for the benefit of our shareholders.
NEW YORK, Dec. 27, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Premier Health Group, Inc. (OTC:PHGRF) (CSE:PHGI)'s subsidiary, HealthVue is focused on developing proprietary technology to deliver quality healthcare through the combination of connected primary care clinics with telemedicine and artificial intelligence. The company currently has an ecosystem of over 100,000 active patients and has plans to rapidly increase that number both domestically and internationally. Earlier this month, Premier Health Group, Inc. (OTC:PHGRF) (CSE:PHGI) also recently announced that as a part of its growth strategy to cover the major verticals associated with primary care, it has signed a binding Letter of Intent to acquire a Vancouver, British Columbia based pharmacy.
True to form, November has proven to be just as lucrative as in previous years. I’m currently in the midst of another winning streak after finishing up my twelfth green day in a row, my sixteenth for the ...
CORAL GABLES, FL / ACCESSWIRE / November 29, 2018 / The healthcare industry is evolving but isn't without its hurdles. While doctors and researchers work to find cures and solutions to both common and ...
NEW YORK, NY / ACCESSWIRE / November 29, 2018 / Shares of Alliqua BioMedical more than doubled on Wednesday on news of a cannabis relatedspin off. Shares of Catalyst Pharmaceuticals also saw big gains on an FDA approval of its rare autoimmune drug, Firdapse. Alliqua BioMedical, Inc. shares closed up 63.19% on Wednesday on skyrocket trading volume compared to usual.
Shares of Alliqua Biomedical Inc (NASDAQ: ALQA ), a company that has unwound itself in phases, were more than doubling in value Wednesday. The stock was trading higher by more than 100 percent at $3.33 ...
CORAL GABLES, FL / ACCESSWIRE / November 28, 2018 / Healthcare stocks and biotechnology stocks have rallied during recent quarters. New developments in technology and drug therapies have boosted excitement within the market. Premier Health Group, Inc. (PHGRF) (PHGI) has engaged discussions with Licensed Producers under the Access to Cannabis for Medical Purposes Regulation, other licensed medical cannabis companies and government officials in order to establish a framework for both patient and physician education.
Alliqua BioMedical, Inc. (ALQA) and TO Pharmaceuticals LLC, a privately held cannabinoid-based pharmaceutical therapy company (“TOP”), today announced plans for Alliqua to spin off its AquaMed Technologies, Inc. (“AquaMed”) subsidiary, which develops, manufactures and markets high water content, electron beam cross-linked aqueous polymer sheet hydrogel products and merge it with TOP, creating a new public bio-pharmaceutical company to be called TO Pharma, focused on discovering, developing and commercializing novel therapeutics based on TOP’s proprietary cannabinoid product platform in a number of FDA-regulated clinical indications and in select OTC markets. Upon consummation of the spin off and merger, Alliqua’s former shareholders will retain a minority stake with the former members of TOP holding a majority interest in TO Pharma. In connection with this transaction, TO Pharma intends to apply to list its shares of common stock on the Nasdaq Stock Market.
A look at who's moving, who's growing and who's dealing in the Bay Area's health care and life sciences space.
LANGHORNE, Pa. and SAN FRANCISCO, Oct. 12, 2018 /PRNewswire/ -- Alliqua BioMedical, Inc. (ALQA) and Adynxx, Inc., a privately held biopharmaceutical company, today announced that they have entered into a definitive merger agreement under which the stockholders of Adynxx would become the majority owners of Alliqua's outstanding common stock on a fully-diluted basis. The proposed merger will create a public clinical-stage pharmaceutical company focused on developing a platform of first-in-class, disease-modifying, non-opioid therapies for the treatment of pain. Adynxx's lead product candidate, brivoligide for the reduction of postoperative pain, is intended to provide long-term pain relief and reduced opioid usage with a single administration at the time of surgery in a group of patients with a greater risk of experiencing increased and prolonged pain following surgery.
Anyone researching Alliqua BioMedical Inc (NASDAQ:ALQA) might want to consider the historical volatility of the share price. Modern finance theory considers volatility to be a measure of risk, and thereRead More...